瑞士Helsinn
成立于 1976 年，总部设在瑞士，在瑞士和爱尔兰拥有多家关联公司，包括 Helsinn Chemicals S.A.和 Helsinn Birex Pharmaceuticals Ltd.等，共同组成HELSINN 集团。
公司策略是于初期获取先进的专利技术，继而进行临床前及临床研究的发展，并且完成药物的研究及制药发展后，于优势竞争市场的国家(美国及欧洲国家)获得市场销售权。然后HELSINN 将产品的专利权逐步赋予其市场伙伴作分销用途。药品的主要成份及制成品由HELSINN 符合品质认证(GMP) 的设施制药来供应给全球顾客。

Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals, with the recent additions of medical devices in therapeutic niche areas.

Helsinn is an important player in Cancer Supportive Care

Helsinn in-licenses early-to-late stage new chemical entities from small and big pharma companies, completes their development through the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development and files and attains their market approval worldwide. The Group markets its products directly through its network of local pharmaceutical partners, selected for their deep in-market knowledge and know-how, whom Helsinn assists and supports with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.

The active pharmaceutical ingredients and the finished dosage products are manufactured to the highest quality, safety and environmental standards, in compliance with U.S. FDA, EU EMA, Swissmedic, Japanese PMDA and PIC requirements at Helsinn’s facilities in Switzerland and Ireland, and supplied worldwide to its customers.